v3.26.1
SIGNIFICANT RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2025
Notes and other explanatory information [abstract]  
SIGNIFICANT RELATED PARTY TRANSACTIONS

30 SIGNIFICANT RELATED PARTY TRANSACTIONS

 

In addition to the related party information disclosed elsewhere in the financial statements, the following significant transactions between the Group and related parties took place on terms agreed between the parties during the financial year:

 

   2023   2024   2025 
   S$   S$   S$ 
                
Associate (disposed in the year)               

Research income

   183,518    115,277    24,167 
                

Related parties

   

 

           

Research income

   -    -    11,962 

Rental income

   -    

-

    8,423 

Proceeds from sale of equity investment

   -    95,775    200,000 
Purchase consideration for acquisition of equity investment   -    -    

18,210

 

Loan receivable

   -    -    30,068 

 

Compensation of directors and key management personnel

 

The remuneration of directors and key management personnel during the year were as follows:

 

   2023   2024   2025 
   S$   S$   S$ 
             
Salaries and bonus   410,699    470,850    349,907 
Directors’ fees   89,830    108,900    81,848 
Defined contribution plans   46,762    51,845    40,476 
Other short-term benefits   7,028    9,906    5,740 
Share-based compensation   -    -    182,862 
Total   554,319    641,501    660,833 
                
Analyzed by:               
Directors of the Company   323,112    453,601    277,210 
Other key management personnel   231,207    187,900    383,623 
Total   554,319    641,501    660,833 

 

 

CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2023, 2024 and 2025